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Abstract 1 
Steviol glycoside sweeteners are extracted and purified from the Stevia rebaudiana Bertoni 2 
plant, a member of the Asteraceae (Compositae) family that is native to South America, where it 3 
has been used for its sweet properties for hundreds of years. With continued rising rates of 4 
obesity, diabetes and other related co-morbidities, in conjunction with global public policies 5 
calling for reductions in sugar intake as a means to help curb these issues, low and no-calorie 6 
sweeteners (LNCS) also known as high-potency sweeteners such as stevia are gaining interest 7 
among consumers and food manufacturers. This appeal is related to stevia being plant-based, 8 
zero calorie and a sweet taste that is 50 – 350 times sweeter than sugar, making it an excellent 9 
choice for use in sugar- and calorie-reduced food and beverage products. Despite the fact that the 10 
safety of stevia has been affirmed by several food regulatory and safety authorities around the 11 
world, insufficient education about stevia’s safety and benefits, including continuing concern 12 
regarding the safety of LNCS in general, deters health professionals and consumers from 13 
recommending and or using stevia. Therefore, the aim of this review and the stevia symposium 14 
that preceded this review at the American Society for Nutrition’s annual conference in 2017 was 15 
to examine in a comprehensive manner, the state of the science for stevia, its safety, potential 16 
health benefits and future research and application. Topics covered include metabolism, safety 17 
and acceptable intake, dietary exposure, impact on blood glucose and insulin levels, energy 18 
intake and weight management, blood pressure, dental caries, naturality and processing, taste and 19 
sensory properties, regulatory status, consumer insights and market trends. Data for stevia is 20 
limited in the case of energy intake and weight management as well as the gut microbiome, 21 
therefore the broader literature on LNCS were reviewed at the symposium and therefore are also 22 
included in this review.  23 
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 24 
Introduction 25 
Stevia rebaudiana Bertoni is a small perennial shrub of the Asteraceae (Compositae) family that 26 
is native to Paraguay, Brazil and Argentina. The leaves of this plant have been used by 27 
indigenous people for centuries in medicines and to sweeten drinks such as maté, a green herbal 28 
tea (1–3). The plant was first brought to the attention of the rest of the world by the botanist 29 
Moises Santiago Bertoni in 1887, who learnt of its properties from the Paraguayan Indians (1, 3). 30 
The chemical characterization of the natural constituents of the plant known as steviol 31 
glycosides, responsible for its distinct sweet taste was not identified until 1931 when two French 32 
chemists, Bridel and Lavielle isolated stevioside, a primary steviol glycoside from stevia leaves 33 
(1). Japan was the first country to commercialize and use crude unpurified extracts of Stevia 34 
rebaudiana in the 1970s on a large-scale (2). Its use eventually spread to several countries in 35 
Asia and Latin America (4). In the 1990s stevia extract was available in the United States (US) 36 
as a dietary supplement in health food stores, however, early formulations were known to have a 37 
licorice flavor with a sweet or bitter after-taste which limited their wide-spread commercial 38 
development (2, 5). The presence of essential oils, tannins and flavonoids in the crude extracts 39 
were partly responsible for some of the off tastes, hence efforts were made to purify extracts and 40 
chemically characterize steviol glycosides (5). 41 
Following the isolation of stevioside, several other steviol glycosides such as 42 
rebaudiosides (Reb) A, B, C, D, E and dulcoside A were identified and isolated from stevia 43 
leaves (6). Generally, the most abundant steviol glycosides in stevia leaves are stevioside (4-13% 44 
w/w), Reb A (2-4%) and Reb C (1-2% w/w) (7, 8). In recent years, more than 40 steviol 45 
glycosides have been identified, e.g., Reb F, G, H, I, J, K, L, M, N, O, Q, stevioside A, D, E etc. 46 
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(9–12). Most of the steviol glycosides derived from the plant are four-ring diterpenes that have a 47 
backbone of 13-hydroxy-ent-kaur-16-en-19-oic acid, known as steviol (1, 12). The various 48 
glycosides differ only in the number and type of monosaccharides attached at the R1 (OH) and 49 
R2 (H) position of the aglycone, steviol. Glucose, fructose, rhamnose, xylose and deoxy glucose 50 
are examples of sugars that are attached to the steviol backbone (12). The two primary steviol 51 
glycosides, stevioside and Reb A differ only by one glucose moiety at R1; stevioside has two 52 
glucose molecules, while Reb A has three. 53 
The stevia plant is now commercially cultivated in Argentina, Brazil, Columbia, 54 
Paraguay, China, Japan, Malaysia, South Korea, Vietnam, Israel, Australia, Kenya, and the 55 
United States. High-purity steviol glycosides are approved as sweeteners by all major regulatory 56 
authorities across the globe and more than 150 countries have approved and/or adopted its use in 57 
foods and beverages. Reb A was the first commercial steviol glycoside launched in the 58 
marketplace (13). 59 
 60 
Metabolism of Steviol Glycosides 61 
The absorption, metabolism and excretion of steviol glycosides have been extensively reviewed 62 
by multiple scientific authorities and experts including the European Food Safety Authority 63 
(EFSA) (14) and recently by Magnuson et al. (15). Steviol glycosides are undigested in the upper 64 
gastrointestinal tract. They are hydrolyzed or degraded only when they come into contact with 65 
microbiota in the colon that cleave the glycosidic linkages, removing the sugar moieties, leaving 66 
behind the steviol backbone that is absorbed systemically, glucuronidated in the liver and 67 
excreted via urine in humans, and via feces in rats (15). 68 
7 
 
 
 
 
In vitro studies demonstrate that human saliva, salivary α-amylase, pepsin, pancreatin, 69 
pancreatic α-amylase as well as jejunal brush border enzymes of mice, rats, and hamsters are not 70 
able to hydrolyze the glycosidic bonds present in stevioside (16). However, the gut microbiota of 71 
humans, rodents and hamsters are able to degrade stevioside to steviol (16). Incubation of 72 
stevioside and Reb A with human fecal microbiota demonstrated that both were completely 73 
hydrolyzed to steviol in 10 and 24 hours, respectively (4, 17). The released sugar moieties are 74 
not absorbed and are most likely quickly utilized by the gut microbes as an energy source, thus 75 
making it a zero calorie sweetener (2). An in vitro model of the intestinal barrier has shown that 76 
the transport of stevioside and Reb A through the monolayers is very low, whereas the absorptive 77 
transport of steviol is high, suggesting that steviol is not metabolized by gut microbiota and is 78 
absorbed from the intestine (18). Bacteroides species are primarily responsible for the hydrolysis 79 
of steviol glycosides in the gut via their beta-glucosidase activity (17).  80 
Evidence from in vitro investigations are consistent with human metabolism studies that  81 
revealed no detectable presence of the glycosides in plasma, suggesting no uptake from the gut 82 
and little or no stevioside or Reb A in urine or feces (19–22). These studies also demonstrate that 83 
steviol is absorbed quickly and transported to the liver where it is conjugated with glucuronic 84 
acid to form steviol glucuronide which in humans is excreted in urine (19–22). Figure 1 85 
summarizes the absorption, metabolism and excretion pathway of steviol glycosides in humans.  86 
Wheeler et al. (21) compared the pharmacokinetics and metabolism of stevioside and Reb 87 
A in healthy adults over a 72-hour period. Peak plasma levels occurred at 8 hours and 12 hours 88 
for stevioside and Reb A, respectively and a half-life (t1/2) of 14-16 hours was observed for both. 89 
Intake of Reb A resulted in significantly lower steviol glucuronide concentrations (59%) than 90 
after stevioside (62%) consumption. The differences in steviol glucuronide levels are attributed 91 
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to the simpler structure and faster bacterial degradation of stevioside compared to Reb A. Fecal 92 
recovery of steviol accounted for approximately 5% of the original dose for both compounds. 93 
The pharmacokinetic analyses revealed that stevioside and Reb A undergo similar metabolic and 94 
elimination processes in humans. 95 
Most of the earlier studies on steviol glycoside metabolism were on Reb A or stevioside 96 
(a.k.a. primary or major glycosides). However, the similarities in the microbial metabolism of 97 
several steviol glycosides were confirmed in in vitro studies of pooled human fecal homogenates 98 
of healthy male and female Asian and Caucasian subjects (12, 23). Reb A, B, C, D, E, F, M, 99 
dulcoside A (a.k.a. minor glycosides) and steviolbioside (an intermediate metabolite), which 100 
contain different sugar moieties (glucose, rhamnose, xylose, fructose and deoxyglucose) and 101 
different linkage types (αβ (1-2), β-1, β (1-2), β (1-3), and β (1-6)), were all degraded to steviol 102 
within 24 to 48 hours. No differences between male and female subjects or between ethnicities 103 
were observed. These data suggest that the different steviol glycosides have similar hydrolysis 104 
rates to that of Reb A and therefore would be expected to have similar steviol absorption rates, 105 
metabolism and pharmacokinetics as Reb A. This was also confirmed in an animal model 106 
comparing the metabolism of Reb A and Reb D (24). These data demonstrate that both major 107 
and minor steviol glycosides appear to share a common metabolic fate. 108 
 109 
Safety and Acceptable Daily Intake of Steviol Glycosides 110 
The safety of steviol glycosides from numerous toxicological, biological, and clinical studies has 111 
been reviewed in several publications (2, 7, 14, 25, 26). As described in the regulatory section of 112 
this review, all major global scientific and regulatory bodies have determined high-purity steviol 113 
glycosides to be safe for consumption by the general population. The majority of the regulatory 114 
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approvals pertain to high-purity (≥ 95%) steviol glycosides. Unpurified crude extracts of stevia 115 
have been reported to cause adverse effects on fertility in animals (27, 28), which have not been 116 
observed with well-characterized high-purity steviol glycosides approved for food and beverage 117 
use. Therefore studies conducted with crude extracts have been determined to be not relevant to 118 
the safety assessment of high-purity steviol glycosides by knowledgeable scientific experts and 119 
regulatory authorities.  120 
Potential effects of high purity steviol glycosides on acute and long-term toxicity, 121 
reproductive and developmental toxicity, and carcinogenicity have been conducted primarily in 122 
rodents but also in other animal models (29–34). Steviol glycosides are excreted primarily as 123 
steviol glucuronide in the urine in humans, whereas in rats, free steviol and steviol glucuronide 124 
are excreted primarily in the feces via the bile, with less than 3% appearing in the urine (2, 35). 125 
This inter-species difference is due to the lower molecular weight threshold for biliary excretion 126 
in rats compared to humans (2). Although the elimination routes of steviol glycosides differ 127 
between humans and rats, this is of no toxicological significance as the metabolism and 128 
pharmacokinetics are similar in the two species (2). In other words, the majority of the tissues 129 
and cells of the body are exposed to similar concentrations of the same metabolites for a similar 130 
amount of time following consumption of steviol glycosides in both species, so the potential for 131 
development of a toxicological effect is similar even though the final route of excretion is 132 
different. Therefore, the rat is an appropriate test animal for safety of consumption of steviol 133 
glycosides and toxicological data generated from rat studies are applicable to humans (2). 134 
The acceptable daily intake (ADI) is the amount of a substance that an individual can 135 
consume daily over a lifetime without any appreciable health risk. It is established by regulatory 136 
agencies based on the results of toxicology testing. The No Observed Adverse Effect Level 137 
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(NOAEL), which is the highest dose fed to animals in long-term studies with no adverse 138 
toxicological effect is considered the basis of the ADI. The NOAEL is divided by safety factors 139 
(typically 100) to account for intra- and inter-species differences to ensure the ADI is safe for all 140 
potential consumers, including subgroups such as children. The current ADI for steviol 141 
glycosides is based on a toxicity and carcinogenicity study that tested stevioside (95.6% purity) 142 
at concentrations of 0, 2.5 and 5% of the diet of rats for 2 years, resulting in consumption levels 143 
of 0, 970 and 2387 mg . kg-1 . d-1 (36). This study evaluated potential effects on physiology (body 144 
weight, food consumption, final organ weight), behavior, ophthalmology, biochemistry (blood 145 
chemistry, hematology, urine analysis, liver enzymes), and histological changes in tissues. At all 146 
the doses tested, stevioside had no effect on cancer development. No adverse effects were 147 
observed in rats consuming stevioside at 2.5% of diet or lower. At the highest dose (5% of diet), 148 
changes were observed for kidney and body weight and survival rates. Therefore, the NOAEL 149 
for this study was 2.5% of the diet, or 970 mg . kg-1 . d-1, and when converted to steviol 150 
equivalents, 383 mg steviol equivalents (SE) . kg-1 . d-1.  151 
Applying a 100-fold safety factor to 383 mg SE results in an ADI of 0 to 4 mg SE . kg-1 . 152 
d-1. The ADI is expressed in steviol equivalents because all steviol glycosides are metabolized to 153 
steviol, allowing the ADI to apply to all steviol glycosides. Steviol glycosides differ in structure 154 
and molecular weight, and therefore contribute relatively different amounts of steviol per gram 155 
of steviol glycoside. Therefore, using the conversion factor of 0.33 for Reb A versus 0.40 for 156 
stevioside, which factors in molecular weight, the number of glucose units and steviol per gram, 157 
the ADI for Reb A equates to 12 mg . kg-1 . d-1 and for stevioside it is 10 mg . kg-1 . d-1.  158 
An important study that established the safety of steviol glycosides for consumption by 159 
pregnant women and children was a reproductive and developmental study of Reb A (> 97% 160 
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purity) (31). Rats were fed up to 2273 mg . kg-1 . d-1 of Reb A for two generations while body 161 
weight, food intake, growth and development, survival, reproductive performance and sexual 162 
maturation were monitored. No adverse reproductive or developmental effects were observed in 163 
any of the generations at the highest dose. Similar results were reported in reproductive 164 
toxicology studies with purified stevioside (29, 37). Early studies in rats with crude extracts of 165 
Stevia rebaudiana had observed reduced fertility (27) or lower seminal vesicle weights compared 166 
to controls (28), but studies with high-purity steviol glycoside extracts (31, 36, 37) have not 167 
observed any negative effects on sexual organs, levels of sexual hormones, mating behavior, 168 
fertility, gestation length, offspring survival and sexual maturation. The lack of adverse effects 169 
following exposures to high doses of high-purity steviol glycoside prior to and during critical 170 
periods of fertility and pregnancy, during lactation, and throughout growth and development of 171 
the offspring to adulthood for two generations demonstrates the safety of steviol glycosides for 172 
consumption by pregnant women and children at or below the established ADI. 173 
Despite the extensive review and conclusions of safety experts that steviol glycosides are 174 
not mutagenic, two publications have questioned whether adequate testing of the genotoxic 175 
potential of steviol glycosides have been performed (38, 39). In response to their concern, Urban 176 
et al. (40) conducted a comprehensive and extensive review of all published in vitro and in vivo 177 
studies. Much of the concern were from a few older in vitro studies where steviol was reported to 178 
be mutagenic using a highly specific bacterial strain, Salmonella typhimurium TM677 which 179 
requires growth conditions that are not applicable to humans. Urban et al.’s (40) review found 180 
consistently negative results for Reb A and steviol, and all negative results for stevioside except 181 
for one study. The in vivo study by Nunes et al. (41) that was positive has been criticized for its 182 
methodology and data interpretation by several reviewers (20, 40, 42, 43). Hence Urban et al. 183 
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(40) concluded that the database of in vitro and in vivo studies for steviol glycosides is robust 184 
with no evidence that steviol glycosides are genotoxic.  185 
In addition to in vitro and animal studies, human safety studies have also been conducted. 186 
Reb A doses of up to 1000 mg/day for 1-4 months and stevioside doses of 750 mg/day for 3 187 
months were well tolerated and had no adverse effects on blood pressure or fasting blood glucose 188 
in healthy, hypertensive and type 1 and type 2 diabetic subjects (44–46). Nor were there any 189 
significant clinical changes in serum chemistry, hematology and urine analysis. Most of the 190 
safety studies have been conducted on Reb A and stevioside because they are the most abundant 191 
steviol glycosides in the Stevia rebaudiana Bertoni plant. However, all major and minor steviol 192 
glycosides are degraded to steviol by human microbiota and therefore share the same metabolic 193 
fate. A series of in vitro tests with human fecal homogenates confirmed this for several of the 194 
minor steviol glycosides Reb B, C, D, E, F, M, dulcoside A, and steviolbioside (12, 23), thus 195 
making the studies on Reb A and stevioside applicable to the minor steviol glycosides as well. 196 
Another concern raised by some is the allergenic potential of steviol glycosides due to the 197 
common taxonomy of the stevia plant with plants that can induce hypersensitivity in some 198 
individuals (e.g., ragweed, goldenrod, chrysanthemum, echinacea, chamomile, lettuce, sunflower 199 
and chicory). A comprehensive literature search found no evidence of allergenic potential of 200 
purified steviol glycosides (47). According to Urban et al. (47) the few cases of allergic reactions 201 
that have been reported in the literature occurred before the introduction of high-purity steviol 202 
glycosides into the marketplace. Similarly, human studies with high-purity steviol glycosides 203 
have reported no negative gastrointestinal side effects such as bloating, gas, diarrhea, nausea or 204 
borborygmus (44–46) that are sometimes associated with certain caloric and nonnutritive 205 
sweeteners that include, fructose, sugar alcohols and allulose, a.k.a. psicose (48–51).  206 
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Overall, the safety data for high-purity steviol glycosides has been thoroughly evaluated 207 
and their use as a plant based zero-calorie sweetener has been approved across the globe. It has 208 
been conclusively determined that foods and beverages containing approved levels of high-purity 209 
stevia leaf extract sweeteners (i.e., steviol glycosides) are safe for all individuals, including 210 
children, pregnant and nursing women, and individuals with diabetes.  211 
 212 
Dietary Exposure 213 
To ensure safety of consumption, the estimated daily intake (EDI) of a food additive should not 214 
exceed the ADI. Hence prior to approval of use, potential intakes are estimated using proposed 215 
food usage levels in various food categories, together with information from food consumption 216 
surveys. The EDI for steviol glycosides has been estimated for various populations (Table 1). In 217 
most instances, the EDI for steviol glycosides is less than the ADI and due to the conservative 218 
nature by which they are assessed, estimated intakes are generally recognized as over estimations 219 
of what might be actual or average consumer intakes.  220 
Surveys have been utilized in various global jurisdictions to determine daily consumption 221 
estimates of high-purity steviol glycosides. The Food and Agriculture Organization/World 222 
Health Organization’s Joint Expert Committee on Food Additives (JECFA) assessed 223 
international dietary exposure estimates using a model that assumed steviol glycosides would 224 
replace all sweeteners used in or as food, based on the relative sweetness of steviol glycosides to 225 
sucrose (52). The Committee estimated maximum intakes of 1.3 - 5 mg SE . kg-1 . d-1 worldwide. 226 
However, the Committee acknowledged that these estimates were highly conservative and 227 
indicated that actual intakes were more likely to be 20–30% of these values (52). Renwick et al. 228 
(53) estimated Reb A intakes for adults, children and diabetic children using equivalent intake 229 
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calculations based on existing LNCS consumption surveys for North America, Australia and 230 
Europe. For the general population, mean intake ranged from 0.4 – 0.7 mg SE . kg-1 . d-1 and for 231 
adults and children, high intakes (90th percentile and above) were 1.1 – 1.7 mg SE .  kg-1 . d-1.   232 
In 2011, Food Standards Australia and New Zealand (FSANZ) during their review to 233 
expand the approval of steviol glycosides considered 3 dietary exposure assessment models; a 234 
30% market share scenario, and two ‘brand loyal’ scenarios (54). Although the 90th percentile 235 
dietary exposures of one of the brand loyal scenarios were 110% of the ADI for Australian 236 
children aged 2–6 years, and 100% of the ADI for New Zealand children aged 5–14 years, the 237 
FSANZ concluded that all 3 models were likely an overestimation. Health Canada (55) used two 238 
approaches in their exposure assessment in 2012. Method 1 substituted all table-top sweeteners 239 
and method 2 assumed maximum authorized use in all food categories. Both approaches resulted 240 
in mean intakes that were well below the ADI. Although the maximum use levels (95th 241 
percentile) marginally exceeded the ADI for children 1-3 and 4-8 years, Health Canada 242 
considered these estimates insignificant from a health perspective.  243 
In 2014, following a request from the European Commission, EFSA carried out a revised 244 
exposure assessment of steviol glycosides (E 960) to those previously done in 2010 and 2011 245 
(56). The EFSA panel concluded that overall, the mean exposure estimates remained below the 246 
ADI of 4 mg SE . kg-1 . d-1 across all population groups, except for toddlers in one country 247 
(Netherlands). However, the panel did not consider this to be significant enough to change the 248 
outcome of the safety assessment. In a re-evaluation, as part of a US GRAS submission (GRN 249 
619) in 2016, estimated intakes of steviol glycosides for the general population were below the 250 
ADI (57). The highest intake was in non-diabetic children, with an intake of 3.28 mg SE . kg-1 . 251 
d-1 at the 95th percentile. Dewinter et al. (58) estimated intakes in type 1 diabetic children who 252 
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are often at the highest risk of exceeding the ADIs for sweeteners due to their potentially high 253 
consumption of sugar substitutes, in their effort to manage a reduced carbohydrate/sugar diet. At 254 
the 95th percentile, all age groups had intakes below the ADI, except for 4-6 year olds, who 255 
exceeded it at 4.75 mg SE . kg-1 . d-1. Due to the conservative nature of the analyses, the authors 256 
concluded that there is little chance that type 1 diabetic children will exceed the ADIs. To date, 257 
based on estimated dietary exposure assessments from different countries and regions of the 258 
world, at typical patterns of consumption of foods and beverages containing steviol glycosides, it 259 
is unlikely that either adults or children, including diabetic adults and children will exceed the 260 
ADI for steviol glycosides. Although there is no safety concern, it would be valuable to have 261 
future research efforts investigate actual dietary intake in adults, children and subsets of the 262 
population that are expected to be high consumers of steviol glycosides and to understand trends 263 
over time.  264 
 265 
Effect of Steviol Glycosides on Health and Related Biomarkers 266 
Background  267 
The new WHO sugars guideline recommends that adults and children reduce their intake of 268 
added sugars to less than 10% of total energy intake, and recommend a further reduction to 269 
below 5% for additional health benefits (59). This guideline is part of WHOs efforts to halt the 270 
rise in diabetes, obesity and premature deaths by 25% by 2025 (59). The UK Scientific Advisory 271 
Commission on Nutrition (SACN) also recommends a reduction of free sugar to ≤ 5% (60). For 272 
an adult, the 10% and 5% guidelines are equivalent to about 50 g and 25 g of sugar per day, 273 
respectively. According to WHO estimates, intake of added sugars among adults ranges from 7-274 
8% of total energy in Hungary and Norway to 16-17% in Spain and the United Kingdom (59). 275 
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The range for children is higher, varying from 12% in Denmark, Slovenia and Sweden to nearly 276 
25% in Portugal (59). In the US, added sugar intake has been declining but remains high, with 277 
adults and 2-18 year olds consuming 14% and 17% of total energy intake, respectively in 2011-278 
2012 (61). These levels are above the recommended maximum of 10% of total energy in the US 279 
(62), as is the case for several other countries.  280 
 281 
Postprandial Blood Glucose and Insulin Effects  282 
It is well established that the intake of sucrose or glucose creates a postprandial spike in blood 283 
glucose and insulin (63). Hence it is of interest to determine if high-purity steviol glycosides 284 
influence postprandial blood glucose and insulin levels. A few human studies have examined this 285 
effect in single-meal evaluations comparing a reduced-sugar/calorie meal with steviol glycosides 286 
versus a full-sugar/calorie meal, while other studies have examined the effect of steviol 287 
glycosides in capsules, as supplements, with no dietary manipulation (Table 2). Three 288 
randomized controlled trials observed a significant reduction in postprandial blood glucose with 289 
purified steviol glycosides utilized in reduced-sugar/calorie meals (64, 65) or supplement form 290 
(66) in healthy subjects and diabetics. Anton et al. (64) observed a significant reduction in 291 
postprandial blood glucose (p < 0.01) and insulin (p < 0.05) levels when stevia was consumed in 292 
a mid-morning meal compared to sucrose in lean and obese subjects. Similarly, Jeppesen et al. 293 
(65) noted a significant decrease in postprandial blood glucose (p < 0.05), including a 156% 294 
lower area under the curve (AUC) for blood glucose (p < 0.01) in subjects with type 2 diabetes. 295 
Gregersen et al. (66) investigated the postprandial effect of 1000 mg of steviol glycosides (91% 296 
stevioside) compared to a 1000 mg maize starch placebo given in capsule form along with an 297 
isocaloric meal in 12 type 2 diabetics who had stopped taking hypoglycemic medication prior to 298 
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the test. Despite no sugar, carbohydrate or calorie difference between the test groups, stevioside 299 
significantly reduced postprandial blood glucose by 18% (p < 0.004) in addition to the AUC for 300 
glucose (p < 0.02) versus placebo. There was a trend towards an increased insulin response 301 
(AUC) and a 40% increase in the insulinogenic index (ratio AUC insulin to AUC glucose) (p < 302 
0.001) when stevioside was consumed versus placebo.   303 
Three other studies (20, 67, 68) observed no significant impact on postprandial blood 304 
glucose in healthy or diabetic subjects when steviol glycosides were consumed as supplements. 305 
However, Jeppesen et al. (67) observed a 45% reduced insulin response in the placebo group (p 306 
<0.05), and an insulin level that was maintained in the stevioside group, suggesting that steviol 307 
glycosides may have a positive effect on beta cell function in type 2 diabetic subjects. In the 308 
IVGTT, the insulin response increased after injection of glucose by 21% in the stevioside group 309 
compared to placebo (p<0.05). The patients included in this study may already have been in a 310 
late stage of diabetes and therefore, may have had limited beta cell function, which may explain 311 
the different results compared to other human and animal studies.  312 
Overall, when the comparison between steviol glycosides and the control involves a 313 
sugar/carbohydrate or calorie differential, postprandial blood glucose reductions have been 314 
observed, and this effect is largely due to a sugar and calorie substitution, as observed in the 315 
studies by Jeppesen et al. (65), and Anton et al. (64). On the other hand, the postprandial blood 316 
glucose decrease observed in the Gregersen et al. (66) study, which had no calorie differential 317 
between treatment and control, suggests that at certain doses, stevioside may have a potential 318 
blood glucose lowering effect in diabetics. These results may not be evident in diabetic subjects 319 
who continue taking their hypoglycemic medication as in the study by Maki et al. (68). 320 
Similarly, Maki et al. (68) did not see any change in postprandial insulin levels, whereas in 321 
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studies where diabetics stopped their hypoglycemic medication, there was evidence of a potential 322 
increase in insulin levels (66, 67). Additional research is needed to more clearly determine if 323 
steviol glycosides have an independent effect on insulin and postprandial blood glucose levels in 324 
individuals with diabetes, if it is specific to any one steviol glycoside, as well as the mechanism 325 
and doses at which these effects may be observed.  326 
 327 
Fasting Blood Glucose and Insulin Effects 328 
Long-term studies indicate high-purity steviol glycosides in supplement form within 329 
interventions that have no dietary carbohydrate or calorie manipulation do not significantly 330 
reduce fasting blood glucose, insulin, or glycated hemoglobin (HbA1c) levels (Supplemental 331 
Table 1). Studies were conducted in healthy subjects, type 1 and  type 2 diabetic subjects, 332 
hyperlipidemic and hypertensive subjects with a wide range of doses (20, 45, 46, 67, 69–71). 333 
These studies had differing protocols involving diabetic subjects, with some continuing their 334 
hypoglycemic medications and others stopping just prior to the beginning of the study. Although 335 
none of the fasting blood glucose measures were significantly changed by the steviol glycoside 336 
treatment, it is noteworthy that in one study 750 mg/d of stevioside maintained fasting blood 337 
glucose levels over a 3-month period, whereas in the placebo group there was a significant 338 
increase compared to baseline among type 1 diabetic subjects who continued their hypoglycemic 339 
medication (46). A similar result was observed in a study by Jeppesen et al. (67), where 1500 340 
mg/d stevioside was consumed for 3 months by type 2 diabetic subjects who had stopped their 341 
hypoglycemic medications. A significant difference between treatment and placebo groups for 342 
fasting glucose (p < 0.007) and HbA1 (p < 0.01) was observed. These findings suggest that 343 
stevioside at levels above the ADI may help maintain a static diabetic state, which could be 344 
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beneficial to individuals with diabetes in minimizing or slowing down the progression of 345 
diabetes. Further, a meta-analysis of several of these studies by Onakpoya and Heneghan, (72) 346 
revealed a small but significant reduction in fasting blood glucose (-0.63 mmol/L, p < 0.00001). 347 
However, the clinical relevance of a reduction of 0.63 mmol/L observed in the meta-analysis 348 
may be limited. 349 
Jeppesen et al. (73) also examined the effect of supplementing 500 mg of steviol 350 
glycosides, together with post-exercise oral carbohydrate versus isocaloric carbohydrate 351 
supplementation on muscle glycogen re-synthesis in 15 male cyclists. The glycogen re-synthesis 352 
rate was increased by 35% (p < 0.02) and glycogen levels were significantly higher (p < 0.009) 353 
with steviol glycosides vs placebo. More research is needed to understand how steviol glycosides 354 
may confer these effects. 355 
 356 
Potential Mechanisms Related to Blood Glucose 357 
It is clear that one indirect way in which steviol glycosides and other LNCS lower postprandial 358 
blood glucose levels is through the displacement of sucrose or other carbohydrates (74). 359 
However, for steviol glycosides, a few in vitro and animal studies suggest a potential 360 
independent and more direct mechanism involving insulin secretion, signaling and release, up-361 
regulation of key genes, and enhanced glucose absorption in primarily diabetic models. Jeppesen 362 
et al. (75) was the first to demonstrate that both stevioside and steviol (1 nmol/L to 1 mmol/L) 363 
dose-dependently enhance insulin secretion from incubated mouse islets in the presence of 364 
glucose (p < 0.05). The insulinotropic effects of stevioside and steviol were critically dependent 365 
on the glucose concentration and occurred at or above 8.3 mmol/L glucose (p < 0.05). To 366 
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determine if stevioside and steviol act directly on pancreatic beta-cells, the beta-cell line INS-1 367 
was used. Both stevioside and steviol potentiated insulin secretion from INS-1 cells (p < 0.05).     368 
Animal studies of steviol glycosides suggest an effect on insulin secretion and sensitivity 369 
and gluconeogenesis. Jeppesen et al. (76) performed an IV glucose tolerance test with and 370 
without 0.2 g . kg-1 . d-1 stevioside in type 2 diabetic Goto-Kakizaki (GK) and normal Wistar 371 
rats. In diabetic rats, stevioside significantly suppressed the blood glucose response (iAUC, p < 372 
0.05) while concurrently increasing the insulin response (iAUC, p < 0.05). Chen et al. (77) 373 
reported that 0.5 mg . kg-1 . d-1 stevioside provided by gastro gavage lowered blood glucose 374 
levels in normal rats, as well as in two models of diabetic rats in a dose-dependent manner, not 375 
only by enhancing insulin secretion but also by slowing down gluconeogenesis in the liver by 376 
decreasing levels of phosphoenol pyruvate carboxykinase (PEPCK), an enzyme involved in the 377 
metabolic pathway of gluconeogenesis. Nordentoft et al. (78) in a 9-week intervention study in 378 
diabetic KKAy mice treated with 20 mg . kg-1 . d-1 observed that the stevioside derivate, 379 
isosteviol, had a high bioavailability from the colon, improved glucose and insulin sensitivity by 380 
upregulating the gene expression of key insulin regulating genes and insulin transcription factors. 381 
Chang et al. (79) observed that a single oral administration of 0.5 mg . kg-1 . d-1 stevioside for 90 382 
minutes decreased plasma glucose concentrations and reversed the glucose-insulin index, a 383 
measure of insulin action on glucose disposal in rats fed fructose-rich chow for 4 weeks. 384 
Repeated administration of stevioside delayed the development of insulin resistance in these rats 385 
and increased the response to exogenous insulin in STZ-diabetic rats. Philippaert et al. (80) 386 
demonstrated that 0.5 mg. kg-1 . d-1 stevioside given orally two hours before a glucose tolerance 387 
test significantly lowered blood glucose levels in normal wild type mice but not in TRPM5 mice. 388 
TRPM5 is a Ca2+-dependent cation channel found in type II taste receptor cells on the tongue and 389 
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in insulin producing β-cells in the pancreas. TRPM5 knockout mice have decreased glucose 390 
tolerance due to impaired glucose-induced insulin release.  391 
A study of Reb A on metabolic syndrome outcomes, suggests similar outcomes to 392 
stevioside. Jeppesen et al. (81) fed rats a high fructose diet for 16 weeks followed by the intake 393 
of 8.4 mg/d Reb A, 16.8 mg/d aspartame or high fructose corn syrup (HFCS) at 13% of total 394 
caloric intake for 8 weeks. Incremental AUC glucose was significantly lower for the Reb A 395 
group compared to the HFCS group (p < 0.05) following a glucose tolerance test. Insulin 396 
resistance measured by HOMA-IR (p < 0.005) as well as hepatic triglyceride content (p < 0.05) 397 
were significantly reduced in the Reb A and aspartame groups. In addition, expression of fatty 398 
acid metabolism genes Srebf1 in liver and Fas in liver and muscle were significantly lower in the 399 
Reb A group compared to the HFCS group (p < 0.001).  400 
Overall the research supports a beneficial effect and no adverse effects of steviol 401 
glycosides for blood glucose management when steviol glycosides are used to reduce or 402 
substitute sugar and calories in a food, meal or diet. The longer-term safety studies that range 403 
from 3 months to a year, in normal individuals and those with diabetes indicate that steviol 404 
glycosides are safe and have a neutral effect on fasting blood glucose, insulin and HbA1c at doses 405 
of up to 1500 mg/d. One meta-analysis suggests a modest reduction in fasting blood glucose. The 406 
doses studied in several long-term studies were well above the ADI. Some preclinical and 407 
clinical studies suggest a potential independent effect of steviol glycosides in lowering 408 
postprandial blood glucose levels, enhancing insulin secretion and improving insulin sensitivity 409 
in diabetic subjects with some mechanistic evidence for these effects. Additional clinical studies 410 
are needed to clarify and confirm these findings. 411 
 412 
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Energy Intake and Weight Control 413 
Full replacement of caloric sweeteners with LNCS in foods and beverages can provide a 414 
desirable sweet taste with little or no sugar and calories. In light of several recent policy 415 
recommendations to reduce sugar in the diet (59, 62, 82), LCNS including steviol glycosides 416 
offer a simple and effective way to reduce both sugar and calories in the diet and thereby also 417 
offer a helpful way to manage both energy intake and body weight.  418 
 419 
Steviol glycosides. To date two studies (64, 83) have evaluated the effect of steviol glycosides on 420 
satiety and energy intake (Table 3). Anton et al. (64) observed no increase in subjective satiety 421 
but found energy intake was significantly decreased over the day when two reduced 422 
energy/sucrose preload meals with steviol glycosides were consumed 20 minutes prior to an ad 423 
libitum lunch and dinner. Thirty-one subjects consumed 309 kcal less during the steviol 424 
glycoside versus sucrose treatment (p < 0.001). There were no differences in energy intake at 425 
lunch or dinner, therefore the daily energy difference was primarily due to the energy difference 426 
in the two preloads. Energy compensation was 24% during the steviol glycoside period. A 427 
second study evaluated the effects of steviol glycosides consumed in water versus a sucrose 428 
control one hour before an ad libitum lunch in 30 males and observed no difference in satiety 429 
ratings but noted a total daily energy intake reduction of 70 kcal (83). The energy compensation 430 
during the steviol glycoside period was 73%. The higher energy compensation in this study 431 
compared to the first could possibly be attributed to several factors including the number and use 432 
of different preloads, the time interval between the preload and the ad libitum meal, and the fact 433 
that the Tey et al. study (83) was not statistically powered to assess energy intake differences, but 434 
was powered to detect a 30% difference of the blood glucose treatment. Across the two studies 435 
23 
 
 
 
 
the average energy compensation was about 50%, similar to the average energy compensation 436 
observed for other LNCS (84). 437 
 438 
Low and no-calorie sweeteners. Due to the absence of clinical trials on the effect of steviol 439 
glycosides on body weight, the symposium included a brief review of the impact of LNCS on 440 
energy intake and body weight, as it would be anticipated that the effect would be similar for 441 
steviol glycosides if a study were carried out. Research demonstrates that there is no precise 442 
physiological balancing of energy intake against energy expenditure. Consumption of energy 443 
either in excess or deficit of immediate energy requirements is not fully compensated for by 444 
adjustments in intake at the next meal or at subsequent meals (85). Hence, reduced energy intake 445 
by LNCS use should be helpful to those attempting to maintain or lose weight. Consistent with 446 
this, a recent meta-analyses of 69 acute and long-term randomized controlled studies in human 447 
participants between 1970 and 2015  found clear evidence that consumption of LNCS in place of 448 
(some) sugar in the diet reduces energy intake and body weight (84). Despite these findings, 449 
claims persist that LNCS hinder rather than help appetite and weight control. 450 
Based on a rodent model, one claim has suggested that by “decoupling” sweetness from 451 
caloric content, LNCS disrupt the animal’s learned ability to regulate energy intake (86, 87). In 452 
these studies, rats that consumed saccharin-sweetened yogurt increased their intake of food that 453 
led to increased weight gain, body fat accumulation and decreased caloric compensation 454 
compared to rats that consumed glucose-sweetened yogurt (86, 87). A basic premise underlying 455 
these studies is that sweet taste is a valid predictor of increased energy intake. However, this can 456 
be challenged, since sweetness does not reliably predict the energy content of foods (88). 457 
Furthermore, there is also the question whether rats, or humans, rely only on simple taste-458 
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nutrient relationships to control energy intake. It is more likely that signals triggered by nutrients 459 
detected in the gut post-absorptively dominate in influencing satiety (85). Recent research has 460 
failed to replicate the earlier “decoupling” findings. In two experiments Boakes et al. (89, 90) 461 
observed that rats intermittently fed glucose gained more weight and/or fat mass than rats 462 
intermittently fed saccharin. This is opposite to the results reported by Swithers et al. (86). The 463 
discrepancy between these two sets of results appears to be explained by the fact that Swithers et 464 
al.’s (86) excluded rats that showed low acceptance of the saccharin-sweetened yogurt. Boakes et 465 
al. (90) show that this biases the sample towards faster-growing rats, as saccharin acceptance is 466 
associated with later weight gain on chow. In other words, the result reported by Swithers et al. 467 
(86) and quoted widely to support the LNCS ‘confuse your body’ claim, is a procedural artefact. 468 
Boakes et al.’s (89) results on the other hand are plausibly explained by a lack of full 469 
compensation for the higher energy content of the glucose-sweetened yogurt. This was 470 
confirmed in a systematic review where 59 out of 68 animal studies of continuous exposure to 471 
LNCS showed no significant weight change or decreased body weight (84). 472 
Another claim suggests that repeated exposure to sweetness encourages a “sweet tooth” 473 
and therefore the increased intake of sweet, energy-containing foods and drinks (91, 92). This 474 
assertion was tested in two recent studies. In a sample of 39 participants, the desire to consume 475 
apple juice, apple, and apple pie was significantly reduced (p< 0.05) when a LNCS drink was 476 
consumed prior to the meal than when water was consumed (93). A second study tested the 477 
effect of consuming sweet drinks on sweet and savory food intake. On 3 separate occasions, 50 478 
participants were presented with a savory snack (Doritos®) and a sweet snack (chocolate chip 479 
cookies) following consumption of water, LNCS soda or a regular sweetened soda (93). The 480 
consumption of the sweet snack was significantly reduced following the intake the LNCS soda (p 481 
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< 0.05) and the regular soda (p < 0.01) compared to water. In contrast, the intake of the savory 482 
snack was not significantly impacted by the ingestion of the sweetened beverages. These results 483 
are consistent with the phenomenon of “sensory-specific satiety”, which is the reduction in liking 484 
or reward value of a recently eaten versus recently uneaten food or taste (94, 95). It is also 485 
consistent with the findings from a 6-month intervention study where participants who 486 
substituted caloric beverages with LNCS beverages significantly reduced their intake of desserts 487 
compared to participants who substituted caloric beverages with water (96). In another study, 488 
participants who reduced their intake of sweet foods and drinks for 3 months showed an increase 489 
in perceived sweet-taste intensity (at low concentrations of sucrose), but no change in perceived 490 
pleasantness of sweet test products (97). Finally, randomized-controlled trials have generally 491 
found no effect on body weight between a diet moderately high in sugars versus a diet where free 492 
sugars were replaced by the isoenergetic exchange of lower sugar carbohydrates (98), again 493 
showing that sweetness per se does not encourage increased energy intake. 494 
For LNCS to successfully contribute to reduced energy intake, it is necessary that 495 
compensatory energy intake not occur. To address this issue a systematic review and meta-496 
analysis examined both short term (< 1 day) and sustained (> 1 day) randomized controlled 497 
studies (84). The short-term analysis evaluated 218 comparisons from 56 papers that examined 498 
the effect of a LNCS preload versus sugar, unsweetened product, water, nothing or placebo 499 
capsules on subsequent energy intake. Most of the comparisons (83%) were LNCS versus sugar, 500 
where it was observed that LNCS when substituted for sugar consistently reduced short-term 501 
energy intake. LNCS intake versus sugar resulted in 70% energy compensation in children and 502 
43% compensation in adults, leading to an average compensation across all studies of 50%. 503 
Energy intake also did not differ for LNCS comparisons with water, unsweetened product, or 504 
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nothing. The sustained energy intake analysis included 10 comparisons from 9 studies that 505 
ranged from 10 days to one year in overweight, obese, and normal weight participants, and in all 506 
instances, the use of LNCS led to a reduction in energy intake. Results of another study 507 
completed after this review were consistent with the findings of Rogers et al. (84) where it was 508 
noted that LNCS beverage consumption with meals did not increase total energy intake, 509 
macronutrient intake or sweet foods selected, either in those who were habitual or non-habitual 510 
consumers (99), contrary to the concern that LNCS might increase energy intake by decoupling 511 
sweetness with energy content, or by enhancing preference for sweets, or other potential 512 
mechanisms reviewed by Mattes and Popkin (100).  513 
The relationship between LNCS intake and body weight have been examined by several 514 
observational (i.e. prospective cohort) studies and randomized controlled trials. Randomized 515 
control studies provide the highest quality of evidence. Table 4 summarizes the findings of 516 
recent systematic reviews and meta-analyses (74, 84, 101–106). Results from 7 systematic 517 
reviews of prospective cohort studies were mixed, with the majority showing no clear trend. One 518 
meta-analysis observed a very slight decrease in BMI (-0.002 kg/m2) (84), whereas another 519 
observed a slight increase in BMI (0.03 kg/m2) and no significant association with body weight 520 
or fat mass (102). In observational studies, it is not possible to control for all potential 521 
confounding factors and therefore the possibility of residual confounding remains, as well as the 522 
possibility of reverse causality (106). Of the 6 systematic reviews and 2 meta-analyses of 523 
randomized controlled trials, most demonstrate a decrease in body weight and or BMI with 524 
LNCS use. Both meta-analyses reported that LNCS use was found to reduce BMI and or body 525 
weight (84, 102). Miller and Perez (102) found LNCS use was significantly associated with 526 
reduced body weight (-0.80 kg), BMI (-0.24 kg/m2), waist circumference (-0.83 cm), and fat 527 
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mass (-1.10 kg). Similarly, Rogers et al. (84) reported a significant reduction in body weight 528 
when LNCS was substituted for sugar (-1.35 kg) or water (-1.24 kg).   529 
Collectively the research to date demonstrate that the consumption of LNCS, including 530 
steviol glycosides consistently help reduce energy intake, contrary to the suggestion that LNCS 531 
might increase energy intake. In addition, studies show that exposure to sweetness does not train 532 
taste preference and encourage a “sweet tooth.” There is in fact, no human clinical study that 533 
would suggest that a sustained exposure to “sweetness” with LNCS would lead to an increase in 534 
energy intake. With regards to steviol glycosides, despite differences in study design, the two 535 
available studies (64, 83) demonstrate an energy reduction benefit with an average energy 536 
compensation of 50%. Overall, the current evidence is consistent with a recent expert consensus 537 
paper (107), which concluded that LNCS help to reduce energy when used in place of higher 538 
energy ingredients. Claims that LNCS increase appetite and body weight are clearly contradicted 539 
by evidence showing that consumption of LNCS can be expected to contribute to healthy weight 540 
management. It is also safe to assume that steviol glycosides would likely result in similar weight 541 
reduction benefits observed in randomized controlled studies of other LNCS.  542 
 543 
Blood Pressure 544 
Six randomized clinical trials with 8 clinical study arms have investigated the effect of steviol 545 
glycosides on blood pressure from 4 weeks to 2 years. Two clinical arms conducted in healthy 546 
adults with normal blood pressure observed no significant differences between consumption of 547 
steviol glycosides and the placebo control (44, 46). Four clinical arms found no significant 548 
impact of steviol glycosides on blood pressure in individuals with type 1 and type 2 diabetes, but 549 
in all four instances, the subjects continued taking their blood pressure medications if they were 550 
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hypertensive  (45, 46, 67). Subjects with mild to moderate hypertension who were not on blood 551 
pressure medication were investigated in two studies and both demonstrated a modest blood 552 
pressure lowering effect with 750 – 1500 mg of stevioside/day (70, 71). The steviol glycoside 553 
interventions were provided in supplement form with no dietary manipulation, with the purpose 554 
of examining their safety and independent effect on blood pressure. 555 
A meta-analysis of 7 randomized controlled trials that assessed steviol glycosides in both 556 
acute single-meal and long-term settings showed a non-significant difference in systolic blood 557 
pressure, but a significant decrease for diastolic blood pressure (-2.24 mm Hg, p=0.03) (72). 558 
However, significant heterogeneity was observed, likely due to differences in the composition of 559 
the steviol glycosides, doses utilized, continued use of blood pressure and antidiabetic 560 
medications by subjects, and the inclusion of subjects with normal blood pressure. Most of these 561 
studies were designed to investigate the safety of steviol glycosides within these contexts, with 562 
several studies using doses that were 3-4 times the ADI with no negative impact, further 563 
supporting the safety of steviol glycosides.  564 
 565 
Gut Microbiota 566 
The human gut microbiota is a large and complex population of microorganisms. Over 1000 567 
species have been identified in total, with around 160 being present in the gut of any one 568 
individual (108). Over 90% of the species fall into two main phyla, Firmicutes and 569 
Bacteroidetes; other common phyla include Actinobacteria, Proteobacteria, Verrucomicrobia and 570 
Fusobacteria (109). There is also evidence that the microbiota may also be involved in obesity 571 
and type 2 diabetes (110). It has however proven more difficult to identify the microorganisms 572 
involved in these conditions. 573 
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The relative proportions of the phyla and their component genera and species, as well as 574 
gut microbial metabolism, can vary markedly between individuals and can be influenced by a 575 
variety of factors including early colonization in the immediate post-natal period, host genetics, 576 
exposure to drugs and environmental chemicals (111). Mounting evidence, however, indicates 577 
that diet, both habitual, and long-term and shorter-term dietary changes, appear to be the most 578 
significant factors influencing the overall composition of the gut microbiota and its functionality.   579 
Because of their extensive use in foods, the interactions of LNCS and gut microbiota 580 
have been the subject of numerous studies in laboratory animals and human subjects, although 581 
LNCS are unlikely to have a clinically meaningful impact because they are consumed at such 582 
low levels. Nevertheless, some studies on saccharin, aspartame and sucralose have shown effects 583 
on microbiota composition or metabolism, but only at very high doses above normal human 584 
consumption, or in studies with design issues or lacking appropriate controls (112–116). LNCS 585 
are a structurally diverse group of compounds that have very different metabolic fates following 586 
consumption as reviewed by Magnuson et al. (15). Most (e.g., acesulfame K, saccharin, 587 
aspartame and sucralose) are not metabolized by gut bacteria. The only two exceptions are 588 
steviol glycosides and cyclamate. The latter is converted by microbiota to cyclohexylamine, 589 
which is subsequently absorbed and excreted in urine (117). 590 
Studies on the impact of steviol glycosides on the gut microbiota are few. Gardana et al. 591 
(17) incubated human fecal suspensions with stevioside or Reb A for 24 hours. Decreases were 592 
seen in numbers of total anaerobes, bacteroides and lactobacilli with stevioside, and in total 593 
aerobes, bifidobacteria and enterococci in incubations with Reb A. In all cases the changes in 594 
number were small (less than 1 log). Similarly, Kunová et al. (118) noted in another in vitro 595 
study that the growth of lactobacilli and bifidobacteria strains were poor in the presence of 596 
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steviol glycosides compared to a glucose control. Denina et al. (119) also observed the lack of 597 
growth of Lactobacillus reuteri strains following the incubation of stevioside and Reb A for 24 598 
hours. A study in BALB/c mice given Reb A orally for 4 weeks at 5.5 mg or 139 mg . kg-1 . d-1   599 
(1.8 mg SE . kg-1 . d-1 or 46 mg SE . kg-1 . d-1) versus water reported no changes in viable counts 600 
of the major groups in faeces, or in diversity indices of total bacteria (120). The only difference 601 
was an increased diversity of lactobacilli at the higher dose, which was over 10 times the ADI of 602 
4 mg SE . kg-1 . d-1. Thus, the current evidence indicates that steviol glycosides have minimal 603 
impact on gut microbiota.  604 
Although there is no effect of steviol glycosides on gut microbiota, data do indicate that 605 
steviol glycosides are metabolized by gut bacteria. The microbiota provides an important role in 606 
the breakdown of dietary ingredients by providing enzymes that are not present in humans (121). 607 
Although glycosylases are common among members of the microbiota, Gardana et al. (17) found 608 
the ability to deglycosylate steviol glycosides appears to reside only within the Bacteroides 609 
genus. Cultures of clostridia, bifidobacteria, coliforms, lactobacilli, enterococci tested were 610 
unable to metabolize stevioside or Reb A. Human variability in hydrolysis of steviol glycosides 611 
is expected to be minimal because Bacteroides is by far one of the most abundant bacterial 612 
groups found in the large intestine (122).  613 
 614 
Dental Caries 615 
The relationship between the consumption of sugar and the incidence of dental caries has been 616 
well established. Two short-term clinical studies have been conducted with stevia. Brambilla et 617 
al. (123) showed that the plaque pH of sucrose (p < 0.01) was significantly lower after a single 618 
rinse versus stevioside or Reb A at identical concentrations at 5, 10, 15 and 30 minutes after 619 
31 
 
 
 
 
rinsing in 20 adults. The reduced growth of S. mutans in a biofilm model was also observed with 620 
stevioside and Reb A. Zanela et al. (124) reported that the accumulation of plaque in 200 621 
children was not reduced in daily mouth rinses containing 0.5% stevioside with 0.05% sodium 622 
fluoride versus 0.12% chlorhexidine with 0.05% sodium fluoride. Counts of S. mutans did not 623 
differ between the groups, but the results may have been confounded as 20% of the children in 624 
all groups had low levels of S. mutans at baseline. Furthermore, a comparison of stevioside with 625 
sucrose may have been a more appropriate comparison rather than chlorhexidine. A study in rat 626 
pups infected with Streptococcus sobrins observed that after 5 weeks of treatment, stevioside and 627 
Reb A were non-cariogenic, in contrast to sucrose where deep fissure and surface caries and the 628 
highest number of S. sobrin counts were noted (125). Two additional in vitro studies report on 629 
the effects of stevia versus typical pharmacological interventions. In one study the inhibitory 630 
effect of chlorhexidine was greater against S. mutans growth than stevia extract in aqueous and 631 
alcoholic solutions (126), and another study demonstrated positive but lower antimicrobial 632 
properties of stevia extracts versus two positive controls, Vancomycin and Azithromycin (127). 633 
Overall, the data suggests that steviol glycosides are not cariogenic and may have beneficial 634 
effects in preventing dental caries versus nutritive sweeteners (e.g., sucrose, high fructose corn 635 
syrup, etc.). However, additional long-term human studies using stevia in place of cariogenic 636 
nutritive sweeteners are warranted. 637 
 638 
Naturality and Processing of Steviol Glycosides 639 
High-purity stevia is extracted and purified from stevia leaves in a manner that is similar to that of 640 
sucrose from sugar cane. Specific parameters involved in the extraction and purification of steviol 641 
glycosides can vary among stevia producers, but in all instances, it starts with the leaves of the 642 
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Stevia rebaudiana Bertoni plant which are harvested, dried and crushed (128, 129). They are 643 
then steeped in warm water similar to a tea infusion (130). Steviol glycosides are soluble in 644 
water due to their monosaccharide moieties and can be extracted in large-scale commercial 645 
processes with a yield of up to 100%. This water extract is dark brown because of other 646 
constituents in the leaves such as protein, fiber, dyes, polyphenols, minerals and salts which are 647 
also extracted. Purification steps remove the non-sugar constituents, and the remaining steviol 648 
glycosides are spray-dried to an off-white intermediate that contains 80-95% steviol glycosides 649 
(131). This end-product is further purified by crystallization using water and or ethanol mixtures 650 
to a white end-product with a purity of at least 95%. These purification steps are physical 651 
processes used to remove unwanted constituents of the leaves that enable steviol glycosides to be 652 
concentrated (13). The process of extraction and purification does not affect the chemical 653 
identity of the steviol glycosides, allowing them to remain as they were when located intact in 654 
the leaves. Some have called into question this conclusion and therefore the naturality or natural 655 
authenticity of high-purity stevia leaf extract. To address this question, a recent study determined 656 
if steviol glycoside molecules are altered and or if their pattern is changed during the process of 657 
extraction and purification from the leaves of the stevia plant to the high-purity end-product 658 
(131).  659 
Three separate batches of a large-scale commercial extraction and purification process 660 
which included the dried leaves (SL), the first water extract (ESL) and the final product, a stevia 661 
leaf extract with a purity of more than 95% (SLE95) were examined (131). All 9 steviol 662 
glycosides (rebaudioside A, -B, -C, -D, -F, rubusoside, steviolbioside, dulcoside A, stevioside) listed in 663 
JECFA’s 2010 specification (129) were detected and were well separated using high 664 
performance liquid chromatography (HPLC) and mass spectrometric detection. The samples 665 
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from all 3 processing steps showed comparable chromatograms with the same pattern and 666 
retention times per the USP reference standard, with the exception of Reb D, which eluted quite 667 
early and could only be detected in the end-product. A mass spectrometric detector was applied, 668 
with HPLC conditions that were comparable to those applied in the first round of testing and the 669 
identities of all 9 steviol glycosides including Reb D were confirmed unambiguously in the 670 
leaves, the first water extract and the high-purity end product (131).  671 
The relative distribution of the sweeteners for every batch was also calculated. It was 672 
found that the relative amounts of Reb A, C and F, dulcoside A and stevioside were comparable 673 
across samples of SLE95, ESL and SL. A slight tendency of depletion was seen for rubusoside, 674 
Reb B and steviolbioside in the SLE95 samples in comparison to the ESL and SL samples in 675 
each series. However, the most salient point is that the 9 steviol glycosides detected in the leaves 676 
were found in the water infusion (ESL samples) and the high-purity end product powder (SLE95 677 
samples) in a similar pattern. These results confirm that steviol glycosides tested in this study are 678 
not chemically modified or degraded during the traditional large-scale commercial extraction and 679 
purification processes used to produce high-purity steviol glycoside sweeteners, thus providing 680 
support for the natural authenticity of steviol glycosides.   681 
 682 
Alternate Technologies for Steviol Glycoside Production 683 
Recent innovations in the production of “steviol glycosides” by glycosylation, bioconversion 684 
(also known as biotransformation) and from genetically modified yeast have focused on reducing 685 
cost and improving taste by minimizing the lingering bitter aftertaste or off-flavors that have 686 
been found with some steviol glycosides.   687 
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Glycosylation is based on the premise that taste is improved when one or more sugar 688 
moieties (usually glucose units) are added to the steviol glycoside molecules extracted from the 689 
stevia plant (132, 133). The process starts with purified stevia leaf extract that is produced using 690 
traditional extraction and purification methods. The extract is then treated with the enzyme 691 
cyclodextrin glycosyl transferase that enables the transfer of glucose from a sugar source such as 692 
corn starch to steviol glycosides, thus modifying their chemical structure. The end product of 693 
glycosylation is a structurally modified form of stevia that consists of several new glycosylated 694 
steviol glycosides that are not found in the stevia plant, and with less of the unaltered steviol 695 
glycosides. 696 
The recent discovery of the genes that encode the biosynthesis of steviol glycosides like 697 
Reb A, D and M has led to the development of Reb A, D and Reb M production in genetically 698 
modified yeast strains of Saccharomyces cerevisiae (134, 135) and Yarrowia lipolytica (136). 699 
These strains of yeast are genetically engineered to express the steviol glycoside metabolic 700 
pathway of the stevia plant, allowing them to produce the enzymes, the intermediates and steviol 701 
glycosides such as, Reb A, D and M in a fermenter with corn dextrose or glucose as a sugar 702 
source. Steviol glycosides produced from genetically modified yeast are not derived from the 703 
stevia plant and do not use any part of the stevia plant in the process.  704 
Another recent technology known as biotransformation or bioconversion starts with 705 
traditionally extracted steviol glycosides such as stevioside or Reb A, that are then transformed 706 
using multiple genetically modified yeast namely, Pichia pastoris strains A and B as noted in a 707 
recent US GRAS notification (137). These genetically modified yeast are engineered to contain 708 
specific enzymes of the biosynthesis pathway of steviol glycosides that selectively transfer 709 
glucose units from a glucose source such as corn dextrose to the starting material, typically 710 
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stevioside, converting it to Reb E and then to Reb M or other desired steviol glycosides. The 711 
end-products, while identical to those found in the stevia plant are not from the plant, but are 712 
made using this bioconversion process.  713 
Traditional extraction and purification of steviol glycosides from the stevia leaves 714 
remains a good way to produce high-purity steviol glycosides that are non-GMO and do not 715 
affect the natural authenticity of the product. Recent proprietary traditional non-GMO breeding 716 
methods have resulted in new stevia varieties such as a variety known as Starleaf™ by 717 
PureCircle Ltd. that has been developed to contain the desirable steviol glycosides, Reb M and 718 
D, at levels that are twenty times higher than historically known in stevia plant varieties (138). 719 
These breeding methods are making available better tasting steviol glycoside sweeteners that are 720 
plant-based, enabling greater reductions in the sugar content of foods and beverages. 721 
 722 
Taste and Sensory Aspects  723 
The intensity of sweetness and flavor profiles differ widely among the different steviol 724 
glycosides (Supplemental Table 2). In general, the sweetness potency of LNCS including 725 
steviol glycosides is dependent on sucrose reference concentrations. For example, the relative 726 
sweetness of Reb A and stevioside are 180 - 350 times than that of sucrose in a 2.5% to 10% 727 
aqueous solution. Recent advances in stevia research have found that some of the minor steviol 728 
glycosides like Reb M and D have a higher sweetness intensity, are more sugar-like in taste and 729 
have minimal aftertaste compared to steviol glycosides like Reb A and stevioside (139–142, 730 
PureCircle, unpublished data). The relative sweetness of all of the minor steviol glycosides to 731 
that of sucrose is not fully known, as the focus has been on combinations of steviol glycosides. 732 
However, from research on proprietary combinations it is known that the minor steviol 733 
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glycosides contribute to both sweetness and flavor modification which can influence how a 734 
combination works in a given food or beverage matrix versus another (PureCircle, proprietary 735 
data). 736 
Replacing sugar in food and beverage products is not simple because sugar provides 737 
texture, viscosity and mouthfeel and has no lingering aftertaste that not all LNCS can mimic 738 
perfectly. For example, in baking, sugar not only provides sweetness, it also contributes to 739 
crispness, cell structure, browning, tenderization and shelf stability, all of which influence 740 
mouthfeel, sweetness, flavor perception and control of water activity. Therefore, when sugar is 741 
reduced in a baked food, bulking agents such as maltodextrin, sugar alcohols or fibers, and 742 
hydrocolloids or proteins are used with stevia, to mimic the characteristics of sugar, provide 743 
moisture and texture that full-sugar versions provide. In recent studies, for 20 - 50% reduced-744 
sugar muffins with stevia, cocoa fiber and inulin were used to provide the optimal level for 745 
texture, sweet taste and flavour (143, 144). Stevia is generally heat stable and may even enhance 746 
flavors in baked goods such as salt, spice and brown aromatics (PureCircle, proprietary data). 747 
Commercially sold high-purity stevia leaf extracts may contain either a single steviol 748 
glycoside (e.g., Reb A) or various combinations of steviol glycosides. Unlike other sweeteners, 749 
stevia’s sweetness is naturally derived from over 40 steviol glycosides, which makes stevia more 750 
complex to work with, versus single compound sweeteners. In addition, some of the challenges 751 
of LNCS including stevia are that they can have “off” tastes such as bitter and metallic, slow-752 
onset and sweet tastes that linger (145). Reb D and Reb M have a relatively clean sweet taste, 753 
while stevioside and Reb A although sweet, can also impart bitter, metallic and or licorice-like 754 
tastes to varying degrees depending on the level used (5). Aside from the range of sweetening 755 
potency, each of the steviol glycosides have different solubilities and exhibit unique sensory and 756 
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functional attributes that also allow them to modify and or enhance flavors such as lemon, fruity, 757 
floral, brown and spicy notes. 758 
Most consumers do not want to compromise on taste and prefer the taste of sucrose. 759 
Therefore, the goal when working with high-potency LNCS is to as closely as possible replicate 760 
the taste and functionality of sucrose. Taste perception is influenced by product matrix and in the 761 
case of stevia, sweet taste can be significantly improved through the use of unique high-purity 762 
steviol glycoside combinations, optimally designed for a given food or beverage matrix. These 763 
innovations point to taste advantages that are far superior versus the use of any single steviol 764 
glycoside such as Reb A or Reb M alone (146), thus helping to achieve maximum sugar 765 
reduction while imparting a more sugar-like taste without adding calories or bitter off notes. 766 
Figure 2 illustrates results from a sensory study with 30 panelists that compared a sucrose 767 
control versus two high-purity stevia leaf extract products in acidified water, namely, Reb A 768 
(97%) and a proprietary ingredient that contained a combination of steviol glycosides (PSB-769 
1198) sold by PureCircle Ltd. Acidified water is used as it is representative of characteristics of 770 
select market beverages that use stevia. Panelists reported a lingering off taste and less upfront 771 
sweetness for the Reb A versus the PSB-1198, demonstrating the advantage of this steviol 772 
glycoside combination. The results indicate the taste profile of PSB-1198 was closer to the taste 773 
profile of sucrose (PureCircle, proprietary data). 774 
Research in the area of taste science can offer additional clues to enhancing stevia’s 775 
overall palatability. Humans perceive 5 basic tastes: sweet, umami, bitter, salty and sour. Of 776 
these, sweet and bitter tastes are of most relevance to stevia (147). Taste perception can change 777 
when multiple taste stimuli are presented together in a food or beverage versus one stimuli, 778 
known as a binary taste interaction (148). The sweet and bitter tastes found in steviol glycosides 779 
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interact and the overall bitterness threshold of steviol glycosides may be affected (149). Sweet 780 
and bitter tastes are detected by different taste receptor cells (147, 150). According to 781 
Backmanov (147), human taste perception, especially bitter tastes, can vary greatly among 782 
individuals, due to genetic variation. A sensory study of 10 trained panelists combined with in 783 
vitro cell-based receptor assays determined how steviol glycosides are sensed by the tongue 784 
(149). Results indicated that two receptors, TAS2R4 and TAS2R14 mediate the bitter taste in 785 
steviol glycosides. The researchers also noted that there are 3 key structural features that appear 786 
to modulate the sweet and bitter taste in steviol glycosides, namely glycone chain length, 787 
pyranose substitution, and the C16 double bond. Steviol glycosides that had more glucose 788 
molecules attached to them were sweeter and less bitter.  789 
Research on sweet taste receptor cells may also be utilized to optimize the taste of steviol 790 
glycosides. The area of a taste receptor cell that tastants bind to is referred to as a docking site 791 
(151). Findings from a docking study on 8 steviol glycosides showed significant variation in the 792 
docking positions of all steviol glycosides tested. Docking scores predicted the sweetness 793 
potency of steviol glycosides. The researchers noted that the interaction of the C-13 and C-19 794 
glucose molecules with a specific set of active docking sites was responsible for its characteristic 795 
taste (152). These results suggest that modifying steviol structures and enabling their binding 796 
towards a specific point in the sweet taste receptor cells may be a useful means of enhancing the 797 
taste quality and sweetness index of steviol glycosides.   798 
 799 
Regulatory Status 800 
The safety and use of steviol glycosides has been reviewed and considered by multiple scientific 801 
bodies and regulatory agencies around the world. High-purity stevia leaf extracts have been 802 
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approved and or adopted for use in foods and beverages in more than 150 countries and or regions 803 
including, the US, European Union, Middle East, Australia, New Zealand, Canada, China, Japan, 804 
Korea, Malaysia, India, Mexico, Brazil, Chile, Paraguay, Argentina, Egypt, Ghana, South Africa, 805 
Kenya, and many other countries in Asia, Europe, Latin America and Africa.  806 
In the US, extracts from stevia have been used as dietary supplements since the 807 
1990s (18) and the use of high-purity steviol glycosides in foods and beverages have been 808 
determined to be “generally recognized as safe” (GRAS) based on the evidence from published 809 
toxicology studies and the review of product specific data by qualified experts who evaluate 810 
safety of use (153). High-purity Reb A received GRAS status (GRN 252) with a no-objection 811 
letter from the US FDA in 2008 (130). To date, according to the US FDA’s GRAS Notice 812 
Inventory the agency has issued more than 40 “no objection” letters on GRAS notices for steviol 813 
glycosides. A high-purity stevia specification, with 9 steviol glycosides (rebaudioside A, -B, -C, -814 
D, -F, rubusoside, steviolbioside, dulcoside A, stevioside) at a minimum 95% purity was 815 
established by the Codex Alimentarius Committee in 2010 (129). In 2011, Codex adopted steviol 816 
glycosides as a food additive with the establishment of food use standards across a variety of food 817 
and beverage categories. The French Food Safety authority was the first in Europe to assess the 818 
safety of Reb A and approve its use in 2009. A favorable scientific opinion by EFSA (14) led to the 819 
approval of ten steviol glycosides by the European Commission (EC) in 2011, which included the 820 
9 approved by JECFA and Reb E. After an initial approval in 2008, FSANZ made revisions in 821 
2010 and 2011 to include higher levels of use and select food categories. Hong Kong and Swiss 822 
approvals happened in 2010, and between 2011 and 2012, Health Canada and several countries in 823 
Asia, Latin America and the Russian Federation approved the use of steviol glycosides for foods 824 
and beverages. Between 2014 and 2016, high-purity steviol glycosides were approved in India, 825 
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several Southeast Asian countries and the Gulf Cooperation Council countries of the Middle East.  826 
       Investigations with lower purity products such as RebA-80 (80% steviol glycoside purity) 827 
and RebA-50 (50% steviol glycoside purity) versus pure Reb A led to the realization that mixtures 828 
of steviol glycosides may offer superior taste to that of pure Reb A. This led to the development of 829 
several stevia sweetener products composed of different combinations and purity levels. Also, the 830 
study of minor steviol glycosides led to an improved understanding of their taste and functionality. 831 
As a result, between 2013 and 2016, there have been 3 US GRAS notices that include Reb M and 832 
or Reb D (134, 154, 155). GRN 473 and 512 are for Reb M extracted from the leaves of the stevia 833 
plant (154, 155). While, GRN 626 is for Reb M and D produced by a genetically engineered strain 834 
of yeast, Saccharomyces cerevisiae (134). Reb M has also been approved by EFSA, FSANZ, and 835 
Health Canada. A recent GRAS notice (GRN 619) with a no-objection letter from the US FDA in 836 
2016 expands the use of stevia to include the safe use of 40 plus steviol glycosides (57). 837 
Additionally, JECFA’s most recent 2017 safety review and proposal supersedes previous 838 
specifications, by proposing the use of all natural-origin steviol glycosides (50 plus) containing a 839 
steviol backbone conjugated to any number, or combination of the principal sugar moieties, in 840 
any of the orientations occurring in the leaves of Stevia rebaudiana Bertoni including, glucose, 841 
rhamnose, xylose, fructose, and deoxyglucose (156). This new proposed specification is 842 
expected to be adopted by Codex in the year 2018.  843 
Of the two known genetically modified yeast Yarrowia lipolytica (136) and Saccharomyces 844 
cerevisiae (135) engineered to produce steviol glycosides, to date JECFA has approved the use of 845 
Reb A produced “from multiple gene donors expressed in Yarrowia lipolytica” at a minimum of 846 
95% purity (157). Additional ingredients using alternate technologies have been approved or have 847 
GRAS status. Between 2011 and 2016, several US GRAS notices with no objection letters from 848 
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the US FDA (e.g., GRN 452, 656, 448, 375, 337, 607) for glucosylated steviol glycosides allowed 849 
their commercialization (132, 158–162). China, the US, Japan, Malaysia and Korea also allow the 850 
use of glucosylated stevia ingredients. In addition, two steviol glycoside ingredients (GRN 667 and 851 
715) produced via bio-conversion have US GRAS status (137, 163).  852 
Food categories and the authorized levels of use for steviol glycosides by regulatory 853 
authorities vary from one region to another. They generally include flavored and carbonated 854 
beverages, dairy products including fermented milk products, edible ices, table top sweeteners, 855 
fruit and vegetable preparations, jams and jellies, cocoa and chocolate products, confectionary and 856 
chewing gum, a variety of sauces, breakfast cereals, some bakery products, processed fish 857 
products, foods for special dietary purposes, alcohol, several regional sweet and savory snack-858 
based products, desserts, and food supplements (164, 165). 859 
Stevia’s primary advantage is that it is a plant-based sweetener of natural-origin. There is 860 
no global definition or agreed upon claim for the term “natural.” However, stevia leaf extract or 861 
steviol glycosides from the Stevia rebaudiana Bertoni plant are clearly defined as a natural 862 
sweetener in the food regulations of Korea, Malaysia and Japan, and reported as the “natural 863 
constituents” of the stevia plant in JECFA’s 69th meeting report (26). The WHO in its recent 864 
publication on reducing sugar in manufactured foods also recognized stevia as a natural sweetener 865 
in its categorization of non-caloric sweeteners (i.e., natural versus artificial) (166). It is generally 866 
acknowledged as a natural-origin sweetener in the US and imagery and “natural” phraseology is 867 
used in many parts of the globe to convey to consumers the use of natural-origin plant-based stevia 868 
sweeteners. The labeling of steviol glycosides in the ingredient list of a food or beverage product 869 
can vary from one country to another. Examples include: stevia leaf extract, steviol glycosides, 870 
Reb A, rebiana, stevia, and in Europe, steviol glycosides (E960), etc.  871 
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 872 
Consumer Insights and Market Trends 873 
Across the globe, increased consumer awareness about the potential health benefits of reducing 874 
calories and sugar has resulted in a shift in consumer preferences for reduced-calorie/sugar foods 875 
and beverages, increasing the potential role of sugar substitutes in helping to address these 876 
preferences. In addition, an increasing interest in clean label, organic and natural LNCS that do 877 
not compromise taste and function has helped to increase awareness about the benefits of stevia 878 
and the increased demand for stevia-based products.  879 
The global growth of stevia is estimated to cross USD one billion by 2021 based on 880 
current market trends (167). The approval of high-purity stevia leaf extracts around the world has 881 
spawned hundreds of food and beverage launches. According to data accessed from Mintel’s 882 
global products database, the number of products with stevia has grown considerably in the past 883 
5 years (168). Since 2011 alone, a total of 14,000 plus products were launched with stevia 884 
globally (Figure 3) and in 2016, 45% of the stevia-based products were in foods and 55% in 885 
beverages.  886 
There is limited peer-reviewed research on consumer and healthcare professional 887 
perception and attitudes regarding LNCS. To determine aided awareness, belief and sentiment 888 
about LNCS including stevia, nationally representative population samples of approximately 889 
1000 adults, aged 18-64 from the US, UK, Germany, China, India, Brazil, and Mexico were 890 
surveyed between 2011-2017 (PureCircle, proprietary data). Fifty percent of the respondents 891 
were male and 50% were female. The surveys contained approximately 30 sweetener-related 892 
questions. The results indicated that across markets at initial launch, stevia awareness ranged 893 
from 8-35% which has grown as high as 77%, in Mexico (Figures 4 A-E). The increase in 894 
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consumer awareness of stevia over time appears to correspond with the increases in product 895 
launches in a given country. In the same studies participants were asked about their impression 896 
of stevia and their belief of stevia as a natural-origin, plant-based ingredient based on a 5-point 897 
Likert scale that ranged from very positive to very negative (Figure 5). Positive responses (very 898 
positive + moderately positive) to the question on the overall impression of stevia ranged from 899 
57-87% across several countries. Belief that stevia is natural ranged from 48-86% across 900 
countries (Figure 5). There appeared to be a relationship between overall impression of stevia 901 
and the belief that stevia is natural and vice-versa.  902 
An online beverage survey of 3361 US adults 18 years and older reported that less than 903 
40% of participants identified added sugars as a primary concern when choosing beverages, 904 
despite dietary guidance to reduce added sugar in the diet (169). This study also reported a 905 
considerable level of consumer misunderstanding or confusion about the types of sugars in 906 
beverages. Another online study in the UK found that 65% of the participants reported no 907 
knowledge of the WHO sugar intake guidelines (170). Subjects (77% female respondents) were 908 
asked to identify and classify 13 caloric sugars (added sugars) or LNCS (aspartame and 909 
saccharin) on the food label, and only 4% correctly classified 10 or more from the ingredient 910 
lists. The authors noted that even well-educated consumers struggled to understand added sugars 911 
on food labels.  912 
A study on the perception of LNCS by dietitians from 5 European countries (France, 913 
Germany, Hungary, Portugal and the United Kingdom) indicates that dietitians are uncertain, 914 
ambivalent or have fears about adverse health effects of LNCS (171). Their knowledge and 915 
opinion of LNCS translated to varied approaches; some dietitians were undecided, some had the 916 
opinion that LNCS should not be used, others felt LNCS should only be used as a transitional 917 
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product, while another group recommended or at least allowed the use of LNCS. Despite the lack 918 
of strong scientific evidence, some dietitians believed that sweet taste stimulates appetite. 919 
Uncertainty about possible adverse health effects and or the safety of LNCS, and distrust of the 920 
industry were reasons why dietitians avoid recommending LNCS. The authors of this study 921 
identified a clear need for authoritative positions and recommendations from appropriate and 922 
trusted sources as key to alleviating the ambiguity, uncertainty and fear.  923 
According to Euromonitor’s July 2017 report on sugar and sweeteners, global consumers 924 
purchased 73 g of total sugars/day in 2015, of which 22% was from table sugar, 19% from fruits 925 
(intrinsic sugar), and 16% from soft drinks (172). Sweet snacks such as biscuits, snack bars and 926 
confectionary jointly provided over 20 g of sugar per capita/day in some of the high sugar 927 
consuming markets. Consumer perception is a critical factor, and according to Euromonitor, 928 
there appears to be a shift towards natural sweeteners, particularly natural full caloric sweeteners 929 
such as honey, coconut sugar, and brown rice sugar. According to Euromonitor, future 930 
development is expected to focus on natural sweeteners (172).  931 
 932 
Authoritative Positions on the Use of Nonnutritive Sweeteners  933 
Nutrition and health-related organizations such as The Academy of Nutrition and Dietetics 934 
(AND), The American Heart Association (AHA) and the American Diabetes Association (ADA) 935 
currently have positions and or scientific statements that support the use of LNCS, including 936 
stevia (74, 173). The AND position paper graded the stevia data that they included in their 937 
evaluation as “fair” and, the overall conclusion for LNCS states that “consumers can safely enjoy 938 
a range of nutritive and nonnutritive sweeteners when consumed within an eating plan that is 939 
guided by current federal nutrition recommendations, such as the Dietary Guidelines for 940 
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Americans and the Dietary Reference Intakes, as well as individual health goals and personal 941 
preference” (173). A 2012 joint scientific statement of the AHA and ADA on the use and health 942 
perspective of LNCS, which included the review of evidence on stevia available at that time, 943 
concluded that when used judiciously, LNCS could facilitate reductions in added sugar intake, 944 
thereby resulting in decreased energy intake and weight loss/control, with beneficial effects on 945 
related metabolic parameters, as long as the substitution does not lead to consuming additional 946 
calories as compensation (74). In addition, the Council on School Health of the American 947 
Academy of Pediatrics in their position on snacks, sweetened beverages, added sugar for schools 948 
also acknowledged the potential use of LNCS for energy reduction in school-aged children 949 
(174). Further, a recent expert panel in the UK concluded that natural origin sweeteners such as 950 
stevia, in blends with sugars, offer consumers a way to help meet the UK recommendation of no 951 
more than 5% of energy from free sugars (175).    952 
Although all major regulatory authorities around the world have approved and support 953 
the use of high-purity steviol glycosides in foods and beverages, policy positions and or 954 
scientific statements on LNCS use similar to the ones by the AND and the AHA/ADA are 955 
lacking in many other parts of the globe. This is a critical gap, as these statements offer 956 
actionable direction for practitioners and healthcare professionals who serve as an important and 957 
respected source of information and advice the public often needs. More research and education 958 
is needed to understand and help both consumers and healthcare professionals make informed 959 
choices based on credible scientific evidence.  960 
 961 
Summary and Conclusion 962 
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Several global and country-level authoritative dietary guidelines recommend a reduction in 963 
added sugar intake due to the growing prevalence of overweight, obesity and diabetes around the 964 
world. These guidelines include recommendations to keep added sugar intake less than 10% of 965 
total calorie intake, and as low as 5% for additional health benefits according to the WHO (59) 966 
and SACN (60). Replacement of caloric sweeteners in foods and beverages with high-purity 967 
stevia leaf extract sweeteners i.e., steviol glycosides is a useful and cost-effective tool in 968 
reducing added sugar intake. 969 
Natural-origin steviol glycosides are the natural sweet constituents of the leaves of the 970 
Stevia rebaudiana Bertoni plant that remain unaltered during extraction and purification. The 971 
safety of consumption of high-purity steviol glycosides at or below the ADI is well established. 972 
Although there are opportunities for additional research as outlined in sections of this 973 
proceedings, evidence to date demonstrates that steviol glycosides are safe, non-cariogenic, non-974 
hypertensive and have minimal impact on the gut microbiota. Human studies have reported no 975 
negative gastrointestinal side effects. When used to displace carbohydrate and sugar in the diet, 976 
studies with high-purity steviol glycosides in healthy individuals and those with diabetes support 977 
a reduction in postprandial blood glucose as well as reduced sugar and energy intake. There is no 978 
evidence that shows an increase in appetite for sugar or sweet products when LNCS or stevia 979 
containing foods are consumed. Therefore, stevia leaf extract sweeteners are a beneficial and 980 
critical tool in sugar and calorie reduction, diabetes, weight management and healthy lifestyles. 981 
Recent innovations have resulted in better tasting natural-origin high-purity stevia leaf extracts 982 
that help both product developers and consumers make the switch from full-calorie/sugar 983 
products to reduced or zero-calorie/sugar-added products to assist in meeting dietary guidelines 984 
consistent with current health and nutrition policy recommendations.  985 
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FIGURE 1 Steviol glycoside metabolism in humans  
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FIGURE 2  Sweetness temporal profile intensity over time. Arrows indicate where the addition of steviol 
glycosides provide upfront sweetness and reduce linger with PSB-1198, a combination of steviol 
glycosides versus Reb A97 alone, making PSB-1198 taste more like sucrose.  
 
FIGURE 3  Number of stevia food and beverage products launched globally: 2011- August 2017. Source: 
Mintel GNPD, data accessed August 2017 (168).  
 
FIGURE 4A-E  Consumer awareness of stevia around the globe. A: United States, B: United Kingdom, C: 
Germany, D: China, E: Mexico. Consumer research time points (year) vary across countries as they are 
influenced by the timing of regulatory approvals of high-purity steviol glycosides, market interest, etc.  
 
FIGURE 5   Positive consumer sentiment and percent that believe stevia is natural. General consumer 
sentiment and belief that stevia is a natural-origin plant based sweetener was assessed by asking 
participants the following questions, respectively: What is your overall impression of each of the following 
sweeteners? How much would you agree or disagree that x sweetener is natural? Each was ranked from 
very positive to very negative (5-point scale). (Stevia was one of the sweeteners evaluated and only data 
for stevia is shown). 
 
 
